Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
X Xie, J Lee, H Liu, T Pearson, AY Lu, D Tripathy… - Molecular cancer …, 2021 - AACR
Triple-negative breast cancer (TNBC) is the most aggressive subgroup of breast cancer, and
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
[PDF][PDF] Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
X Xie, J Lee, H Liu, T Pearson, AY Lu… - Mol Cancer …, 2021 - scholar.archive.org
Triple-negative breast cancer (TNBC) is the most aggressive subgroup of breast cancer, and
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
Birinapant enhances gemcitabine's antitumor efficacy in triple-negative breast cancer by inducing intrinsic pathway–dependent apoptosis
X Xie, J Lee, H Liu, T Pearson… - Molecular cancer …, 2021 - mdanderson.elsevierpure.com
Triple-negative breast cancer (TNBC) is the most aggressive subgroup of breast cancer, and
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
X Xie, J Lee, H Liu, T Pearson, AY Lu… - Molecular Cancer …, 2020 - europepmc.org
Triple-negative breast cancer (TNBC) is the most aggressive subgroup of breast cancer, and
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
Birinapant enhances gemcitabine's anti-tumor efficacy in triple-negative breast cancer by inducing intrinsic pathway-dependent apoptosis
X Xie, J Lee, T Pearson, AY Lu, D Tripathy, GR Devi… - Cancer Research, 2020 - AACR
Background: Apoptosis resistance is a hallmark of cancer, and apoptosis regulators have
been targeted for cancer treatment. A class of such regulators is inhibitor of apoptosis …
been targeted for cancer treatment. A class of such regulators is inhibitor of apoptosis …
[PDF][PDF] Birinapant Enhances Gemcitabine's Anti-tumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
X Xie, J Lee, H Liu, T Pearson, AY Lu, D Tripathy… - Mol Cancer …, 2021 - researchgate.net
Triple-negative breast cancer (TNBC) is the most aggressive subgroup of breast cancer, and
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
[HTML][HTML] Birinapant Enhances Gemcitabine's Anti-tumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
X Xie, J Lee, H Liu, T Pearson, AY Lu… - Molecular cancer …, 2021 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is the most aggressive subgroup of breast cancer, and
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis
X Xie, J Lee, H Liu, T Pearson, AY Lu… - Molecular cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is the most aggressive subgroup of breast cancer, and
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …
patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of …